ASH 2022 | The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, comments on the importance of diagnosing immunoglobulin (Ig) heavy chain (AH) amyloidosis, explaining that a significant proportion of patients with normal levels of Ig light chain can have heavy chain amyloid deposits. Consequently, Dr Gertz encourages clinicians and hematologists to consider the possibility of AH amyloidosis when they show symptoms associated with monoclonal gammopathies in the presence of normal free light chain levels and ratios. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Ionis/Akcea: Other: personal fees; Prothena: Other: personal fees; Sanofi: Other: personal fees; Janssen: Other: personal fees; Aptitude Healthgrants: Other: personal fees; Ashfield: Other: personal fees; Juno: Other: personal fees; Physicians Education Resource: Other: personal fees; Abbvie: Membership on an entity’s Board of Directors or advisory committees, Other: personal fees from Data Safety Monitoring Board; Johnson & Johnson: Other: personal fees; Celgene: Other: personal fees; Research to Practice: Other: personal fees; Sorrento: Other: personal fees; i3Health: Other: Development of educational materials for i3Health.
